The trade association for brand-name drug manufacturers could soon count the largest generic drug maker among its members—and the brand-name companies aren’t entirely comfortable with the idea.

The risks of “stem cell tourism” might be overplayed, according to a new paper published June 30 in the journal Cell Stem Cell. But only because the real risks of unregulated stem cells might actually be within the U.S. 

Nearly 13 percent of the 12.7 million people who bought coverage on the Affordable Care Act’s health insurance marketplaces for 2016 had dropped out by the end of March.

AstraZeneca’s cholesterol medicine Crestor’s patent protection is set to expire July 8, according to FDA standards, but the company has other plans for the drug. 

The House Energy and Commerce Committee has issued a subpoena to HHS Secretary Sylvia Burwell to turn over documents related to the Affordable Care Act’s reinsurance program, which Republican members on the committee claim has been improperly funded by the agency.

Vice President Joe Biden led a major step toward completing his “moonshot” task of curing cancer June 29, when he spoke at the first Cancer Moonshot Summit. 

The Food and Drug Administration (FDA) has given a thumbs up to a test hospitals can use to identify certain types of antibiotic-resistant infections more quickly.

While defending a proposal to test changes to how reimbursements are calculated under Medicare Part B, CMS Chief Medical Officer Patrick Conway, MD, told a panel of federal lawmakers the agency would alter the plan based on concerns from physicians and lawmakers.